Nassir Habboubi

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, Kendra Sweet, Anthony S. Stein et al. · Journal of Clinical Oncology · 2022 · 68 citations · Full text

Medicine, Clinical Sciences, Oncology +15

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Daniel G. Haller, Mace L. Rothenberg, A. Wong et al. · Journal of Clinical Oncology · 2008 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Non-Hodgkin's lymphomas in the Middle East. A study of 417 patients with emphasis on special features

Philip A. Salem, Elias Anaissie, Charles Allam et al. · Cancer · 1986 · 49 citations · Full text

Medicine, Hematology, Pathology +15

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Aditya Bardia, François‐Clément Bidard, Patrick Neven et al. · Cancer Research · 2023 · 42 citations

Medicine, Endocrinology, Oncology +17